BIOME AUSTRALIA LIMITED (BIO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BIO - BIOME AUSTRALIA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Household & Personal Products
Debt/EBITDA: -0.37
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.615

22 Jul
2024

-0.040

OPEN

$0.65

-6.11%

HIGH

$0.66

1,144,415

LOW

$0.61

TARGET
$0.80 30.1% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
BIO: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 1.5 - 1.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 2020202120222023
EPS Basic xxxxxxxxx-1.5
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx7.2 M
Book Value Per Share xxxxxxxxx1.8
Net Operating Cash Flow xxxxxxxxx-3.5 M
Net Profit Margin xxxxxxxxx-42.55 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2020202120222023
Return on Capital Employed xxxxxxxxx-60.89 %
Return on Invested Capital xxxxxxxxx-53.97 %
Return on Assets xxxxxxxxx-38.94 %
Return on Equity xxxxxxxxx-60.89 %
Return on Total Capital xxxxxxxxx-55.92 %
Free Cash Flow ex dividends xxxxxxxxx-3.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2020202120222023
Short-Term Debt xxxxxxxxx0 M
Long Term Debt xxxxxxxxx1 M
Total Debt xxxxxxxxx1 M
Goodwill - Gross xxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxx2 M
Price To Book Value xxxxxxxxx4.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2020202120222023
Capex xxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxx5.54 %
Cost of Goods Sold xxxxxxxxx3 M
Selling, General & Admin. Exp & Other xxxxxxxxx7 M
Research & Development xxxxxxxxx-
Investments - Total xxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

16/07/2024

1

Buy

$0.80

30.08%

Displaying the fastest sales growth of the past five quarters, notes Bell Potter, Biome Australia's June quarter increased by 88% on the previous corresponding period. 

Also, operating cash flow (OCF) nearly doubled in the March quarter, and was the third successive positive quarter, highlights the broker. 

Bell Potter attributes sales growth to the release of new products over FY24 and a 25% increase in distribution footprint across pharmacy and health practitioners. Pharmacy sales account for around 66% of total sales, note the analysts.

The target rises to 80c from 73c as the broker lowers the assumed discount rate to 11.8% from 12.5%.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -1.10 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.20 cents.
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >

BIO STOCK CHART

FNArena News on BIO

1
Australian Broker Call *Extra* Edition – Nov 01, 2022

Nov 01 2022 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 06, 2022

Sep 06 2022 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 04, 2022

Aug 04 2022 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Mar 03, 2022

Mar 03 2022 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Dec 20, 2021

Dec 20 2021 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Shares Breaking Free

10:30 AM - Technicals
2
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
3
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
4
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
5
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
6
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
7
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
8
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
9
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
10
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps